Skip to main content
. 2011 Jan 10;102(3):597–604. doi: 10.1111/j.1349-7006.2010.01817.x

Figure 3.

Figure 3

 Downregulation of the Akt‐mediated Wnt/β‐catenin pathway by KO‐202125 in MDA‐MB‐231 human breast cancer cells. Cells were treated with vehicle or 4 μM KO‐202125 for 72 h. (a) The effect of KO‐202125 on the Akt‐mediated canonical Wnt signaling pathway was determined by immunoblotting. (b) The effect of KO‐202125 on cytoplasmic/nuclear localization of β‐catenin was examined by biochemical fractionation. (c) The effect of KO‐202125 on subcellular localization of β‐catenin was assessed by immunofluorescence microscopy and the result was quantified by counting 1000 total cells each in three independent experiments (d) The effect of KO‐202125 on TCF4 promoter activity was determined by a promoter assay as described in the Materials and Methods. FOP, reporter assay with FOP‐FLASH construct; TOP, reporter assay with TOP‐FLASH construct; RLU, relative light unit. Each data was statistically analyzed with the Student’s t‐test. Data are presented as mean ± SD. *Statistically significant difference of P < 0.05.